Table 4:
Exposure* | No. (%) of cases† n = 12 874 |
No. (%) of controls n = 1 240 431 |
OR (95% CI) | |
---|---|---|---|---|
Crude‡ | Adjusted§ | |||
Nonuse of antibiotics | 5060 (39.3) | 601 049 (48.5) | 1.00 (ref) | 1.00 (ref) |
Use of azithromycin | ||||
Current use | 30 (0.2) | 1344 (0.1) | 2.83 (1.97–4.08) | 1.97 (1.35–2.86) |
Recent use | 109 (0.8) | 8315 (0.7) | 1.65 (1.36–2.00) | 1.12 (0.92–1.37) |
Past use | 187 (1.5) | 18 000 (1.5) | 1.28 (1.10–1.48) | 1.10 (0.95–1.28) |
Use of other antibiotics¶ | ||||
Current use | 1026 (8.0) | 52 543 (4.2) | 2.43 (2.27–2.60) | 1.83 (1.71–1.97) |
Recent use | 2617 (20.3) | 193 154 (15.6) | 1.69 (1.61–1.77) | 1.32 (1.25–1.39) |
Past use | 3845 (29.9) | 366 026 (29.5) | 1.29 (1.23–1.34) | 1.11 (1.06–1.16) |
Note: CI = confidence interval, OR = odds ratio, ref = reference category.
Current = exposure period covered the index date (occurrence of ventricular arrhythmia) or ended within 7 days before the index date; recent = exposure period ended between 7 and 89 days before the index date; past = exposure period ended between 90 and 364 days before the index date.
Current users of both azithromycin and other antibiotics were not included in the analysis.
The crude ORs are estimated for matched case-control pairs and cannot be calculated directly from the table above.
Adjusted for risk factors of ventricular arrhythmia: atrial flutter/fibrillation, cardiomyopathy, coronary artery disease, cerebrovascular disorders, chronic obstructive pulmonary disease, electrolytic imbalance, heart failure, hypertension, diabetes mellitus, lipid disorders, peripheral arterial disease, hypothyroidism, prior use of antiarrhythmic drugs, concomitant use of drugs known to cause hypokalemia, and concomitant use of drugs known to prolong QT interval.
Does not include amoxicillin.